Holen Sie sich die Stockscreener-App
4.53
5.10%
0.22
Handel nachbörslich:
4.51
-0.02
-0.44%
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
Arbutus Biopharma Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Arbutus: Q4 Earnings Snapshot - theheraldreview.com
Arbutus Biopharma Hits Day Low of $4.21 Amid Price Pressure - Markets Mojo
Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives - simplywall.st
Arbutus Biopharma 2025 Financials: Reduced Annual Loss, Revenue GrowthNews and Statistics - IndexBox
Arbutus Biopharma Corporation (ABUS) Form 8-K Filing Details, Key Financials, and Company Information - Minichart
Arbutus Biopharma earnings beat by $0.02, revenue topped estimates - Investing.com
Arbutus Biopharma 2025 Annual Report: Clinical Pipeline, Patent Litigation, and Strategic Outlook - Minichart
Arbutus Biopharma Corp expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Arbutus Biopharma (ABUS) Misses EPS Estimates but Exceeds Revenue Expectations - GuruFocus
Arbutus: Fourth Quarter Financial Results Overview - Bitget
Arbutus Biopharma (NASDAQ:ABUS) Posts Earnings Results - MarketBeat
Arbutus Biopharma (Nasdaq: ABUS) trims 2025 loss after $2.25B Moderna settlement - Stock Titan
Moderna settlement reshapes Arbutus Biopharma (ABUS) with $950M payout - Stock Titan
Arbutus' imdusiran nets two more HBV functional cures; Q3 2026 capital return eyed after $2.25B deal - Stock Titan
Market Moves: Is Arbutus Biopharma Corporation attractive at current valuation2026 Bull vs Bear & AI Based Trade Execution Alerts - baoquankhu1.vn
Arbutus Biopharma (ABUS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Moderna to pay about $1 billion to settle Arbutus litigation - MSN
Foursixthree Capital LP Has $8.99 Million Stake in Arbutus Biopharma Corporation $ABUS - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Shares Down 8.4%Time to Sell? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Moderna Settles Patent Litigation with Arbutus et al. - JD Supra
Arbutus Biopharma Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential - Investing.com
Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation - Investing.com
Moderna to Pay About $1 Billion to Settle Arbutus Litigation - Claims Journal
Here's Arbutus Biopharma's share of $950M Moderna settlement - The Business Journals
Arbutus Biopharma (NASDAQ:ABUS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Arbutus Biopharma (ABUS) Reaches Settlement with Moderna Over Pa - GuruFocus
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal By Investing.com - Investing.com Canada
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS - Finviz
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal - Investing.com
ABUS: Key Developments and Market Impact - GuruFocus
Moderna's $950 Million Settlement Clears Legal Overhang, Stock SoarsModerna (NASDAQ:MRNA) - Benzinga
Moderna to pay about US$1 bil to settle Arbutus litigation - The Edge Malaysia
Genevant and Arbutus agree $2.25 billion global settlement with Moderna - The Pharma Letter
Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Moderna Shares Rise 16% After Company Enters Settlement Agreement With Arbutus Biopharma, Genevant Sciences - Bitget
Moderna To Pay At Least $950M To End COVID-19 Vax IP Fight - Law360
Moderna to pay Genevant Sciences and Arbutus Biopharma up to $2.25 billion in global patent settlement - PharmaLive
Moderna agrees to pay nearly $1B to settle Covid vaccine patent battle - The Business Journals
Arbutus Biopharma (ABUS) and Genevant Reach $2.25 Billion Settle - GuruFocus
Arbutus Biopharma Reaches Transformative Global Settlement With Moderna - TipRanks
Roivant, Arbutus Biopharma stocks surges on $2.25B Moderna settlement - Investing.com
Roivant's Genevant and Arbutus reach $2.25 billion settlement with Moderna - StreetInsider
Arbutus Biopharma (Nasdaq: ABUS) details $2.25B Moderna patent settlement - Stock Titan
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewswire
Moderna Royalty Loss Raises Covid-Shot Trial Stakes (Correct) - Bloomberg Law News
Arbutus Biopharma wins partial summary judgment on Moderna defenses; enablement dispute to go to jury - TradingView
Key patent ruling boosts Arbutus Biopharma (NASDAQ: ABUS) in Moderna LNP case - Stock Titan
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - Intellectia AI
Delaware Court Narrows Moderna’s Invalidity Defenses Ahead of Arbutus LNP Patent Trial - IPWatchdog.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Moderna Loses Key Covid-Shot Patent Defenses Before Jury Trial - Bloomberg Law News
What insider trading reveals about Arbutus Biopharma Corporation stockMarket Risk Summary & Fast Entry and Exit Trade Plans - mfd.ru
Will Arbutus Biopharma Corporation stock remain a Wall Street favorite2025 Top Decliners & Comprehensive Market Scan Insights - mfd.ru
Moving Averages: How does Arbutus Biopharma Corporation correlate with NasdaqWeekly Investment Report & Smart Investment Allocation Insights - baoquankhu1.vn
Court narrows but sustains Arbutus (NASDAQ: ABUS) patent claims in Moderna COVID-19 vaccine fight - Stock Titan
PATENT—D. Del.: Most COVID-19... - VitalLaw.com
Moderna Again Fails to Shift Most Covid-Shot Patent Costs to US - Bloomberg Law News
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):